2025-524480-21-00RecruitingPhase 1
The clinical trial to study a new drug, AP-2.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 15 Nov 2025
- Start date
- 24 Apr 2026
- Lead sponsor
- Molefy Pharma S.L.
- Diseases
- Frontotemporal dementia
- EU CT number
- 2025-524480-21-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 64
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 to 64 years. It studies a new drug, AP-2, for ALS and related conditions such as frontotemporal dementia and Alexander disease. Healthy volunteers can also join.
- Age
- 18 to 64 years
- Sex
- Men only
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario de la Princesa | Madrid | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.